



2024 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION TRAINING

***Clinical Guidance for Treating Pregnant and Parenting Women*
with Opioid Use Disorder and Their Infants***

*This training also uses the term “people” to include women, nonbinary, transgender, or non-conforming individuals experiencing pregnancy or in a parenting role.

| Friday, May 10, 2024 Virtual Training | | | |
|---|--------|---|--|
| Time | Module | Topic and Activities | Speaker(s) |
| 8:30 | | Welcome and Opening Remarks | Jean Bennett |
| 8:40 | | Introduction | Hendrée Jones |
| 8:45 | 1 | Background on Opioid Use Disorder in Pregnant Women | Essence Hairston |
| | | Case Study | |
| | | Video #1, #2 | |
| | | Q&A | |
| 9:30 | 2 | Pharmacotherapy for Pregnant Women with Opioid Use Disorder, Pt. 1 | Katie Mark |
| | | Video #3 | |
| | | Q&A | |
| 10:15 | | Break | |
| 10:30 | 2 | Pharmacotherapy for Pregnant Women with Opioid Use Disorder, Pt. 2 | Katie Mark |
| | | Video #4, #5, #6 | |
| | | Q&A | |
| 11:30 | 3 | Prenatal Care | Hendrée Jones |
| | | Video #7, #8 | |
| | | Q&A | |
| 12:15 | | Town Hall | Jean Bennett and Faculty/State Leaders |
| 1:00 | 4 | Preparing for Labor and Delivery | Katie Mark |
| | | Essential Information for Women Who Have Had No Prenatal Care | |
| | | Case Study and Q&A | |
| 1:45 | 5 | Infant Care | Hendrée Jones |
| | | Video #9, #10, #11 | |
| | | Q&A | |
| 2:30 | | Break | |
| 2:45 | 6 | Postnatal Care | Essence Hairston |
| | | Video #12, #13, #14, #15 | |
| | | Q&A | |
| 3:30 | | Identifying Ideas for Implementation Action Planning: Customizing application of course information | Jean Bennett and Faculty |
| 4:50 | | Wrap Up & Final Thoughts | Jean Bennett and Faculty |
| 5:00 | | Adjourn | |



2024 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION TRAINING

Clinical Guidance for Treating Pregnant and Parenting People with Opioid Use Disorder and Their Infants*

*This training also uses the term “people” to include women, nonbinary, transgender, or non-conforming individuals experiencing pregnancy or in a parenting role.

PRESENTED BY:

University of Maryland School of Medicine and Substance Abuse and Mental Health Services Administration

Training Objectives: At the conclusion of this activity, participants will be able to:

1. Describe the current epidemiology of opioid use among pregnant and parenting women;
2. Use appropriate strategies to obtain patients’ informed consent and ensure shared decision making between the pregnant woman or new mother and the healthcare provider;
3. Recognize risk factors for potential misuse, abuse, and diversion of prescribed opioid medications among pregnant women;
4. Use state Prescription Drug Monitoring Programs (PDMP) data to obtain a history of the prescriptions for reportable controlled substances dispensed to the patient;
5. Educate and counsel pregnant patients with OUD about different treatment options and the potential social, medical and legal consequences of each form of therapy and of opioid use during pregnancy;
6. Select appropriate pharmacotherapy for initiating medication-assisted treatment (MAT) in pregnant women with OUD and adjust pharmacology in response to the physiological changes of pregnancy;
7. Choose appropriate techniques to screen for and treat neonatal abstinence syndrome (NAS) and neonatal opioid withdrawal (NOW);
8. Prepare and execute discharge plans for mothers and infants; and
9. Coordinate care among healthcare professionals to address the comprehensive needs of the patient and infant.

Continuing Education Information:

Faculty Disclosure Information - There are no relationships to disclosure for our presenters.

Continuing Medical Education

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Maryland School of Medicine and the Substance Abuse and Mental Health Services Administration (SAMHSA). The University of Maryland School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The University of Maryland School of Medicine designates this Live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact Hours: 7.0

Counselors

The University of Maryland School of Medicine National Center for School Mental Health is authorized by of the Maryland Board of Examiners of Professional Counselors and Therapists for continuing education credits for licensed professional counselors and therapists in Maryland. This training qualifies for Continuing Education for Live Session, Category 1/A for continuing education units.

Psychologists

The University of Maryland School of Medicine National Center for School Mental Health is authorized by the Maryland Board of Examiners of Psychologists for continuing education credits for licensed psychologists in Maryland. This training qualifies for Continuing Education for Live Sessions, Category A, for continuing education units.

Social Workers

The University of Maryland School of Medicine National Center for School Mental Health is authorized by the Board of Social Work Examiners in Maryland to sponsor social work continuing education learning activities and maintains full responsibility for this program. This training qualifies for Continuing Education for Live Session, Category 1, for continuing education units.

CEs – Other Health Professionals

Please consult with your accreditation agency on applying above CME or CE to your professional continuing education.

Participation in this no-cost, virtual training meets the new one-time, eight-hour CME requirement for Drug Enforcement Administration-registered physicians and physician assistants, as outlined in the Consolidated Appropriations Act of 2023.

Resource Links:

- **SAMHSA Clinical Guidance Publication**
link <https://store.samhsa.gov/sites/default/files/sma18-5054.pdf>
- **2023 Advisory Link**
<https://store.samhsa.gov/sites/default/files/pep23-02-01-002.pdf>
- **Working with Child Protective Services to Support Pregnant and Parenting People, Their Infants, and Families Affected by Substance Use Disorders: A Factsheet for Health Care Providers**
<https://ncsacw.acf.hhs.gov/files/healthcare-cps-pregnant-parenting-sud.pdf>

SAMHSA Regional Office Leadership for follow up questions, learning community interest:

Jean.Bennett@samhsa.hhs.gov

Jeanne.Tuono@samhsa.hhs.gov